Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6956MR)

This product GTTS-WQ6956MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6956MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7392MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GA101
GTTS-WQ15454MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA U3-1287
GTTS-WQ3691MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ2672MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 655
GTTS-WQ11786MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MK-3222
GTTS-WQ14617MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SC0001
GTTS-WQ10028MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA L19-131 I
GTTS-WQ10909MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MABT5102A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW